Moderna, Inc. (MRNA)
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More
Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back. The S&P 500 and Nasdaq slid about 0.2%, while the Dow dropped 0.4%.
Moderna stock slides as FDA moves to tighten vaccine guidelines
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock fell sharply on the news that the Food and Drug Administration (FDA) plans to implement stricter approval requirements for vaccines. The announcement raised investor concerns about potential delays and increased scrutiny for the company's pipeline of new products.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Moderna, Inc. (MRNA) Analyst/Investor Day Transcript
Moderna, Inc. ( MRNA ) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Stéphane Bancel - CEO & Director Stephen Hoge - President Jerh Collins - Chief Technical Operations & Quality Officer James Mock - Chief Financial Officer Jacqueline Miller - Chief Medical Officer Darin Edwards Raffael Nachbagauer Christine Shaw Kyle Holen Michelle Brown Rose Loughlin - Executive Vice President of Research Lavina Talukdar - Senior VP & Head of Investor Relations Rituparna Das Jeff Savard Craig Kennedy Jamie Collins Suzanne Tracy Wenhao Liu Andrew Semmes Amanda Sorrento Nathan Sauveur John Ward Daniel Kulp Kristine McKinney Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Elizabeth Webster - Goldman Sachs Group, Inc., Research Division Lili Nsongo - Leerink Partners LLC, Research Division Alexandria Hammond - Wolfe Research, LLC Conversation Stéphane Bancel CEO & Director Good morning, good afternoon.
What Is Going On With Moderna Stock?
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over the last 5 days, leading to a current market capitalization of around $10 billion.
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported earnings per share (EPS) of 3 cents.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per share a year ago.
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Moderna: Focus On Cancer Vaccines, Not Buyout
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRNA Covid vaccines boosting cancer survival rates drive renewed optimism for the drug pipeline. The company maintains a strong cash position, reduced costs, and a robust drug pipeline, with cancer vaccines representing the largest market opportunity.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
